| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding | |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | Entrez:608 MIM:109545 HGNC:HGNC:11913 Ensembl:ENSG00000048462 AllianceGenome:HGNC:11913 | |
| Description | TNF receptor superfamily member 17 | |||||
| GTO ID | GTC0608 |
| Trial ID | ChiCTR1900026219 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BCMA CAR-T cells |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | Combination of humanized anti-CD19 CAR-T and anti-BCMA CAR-T versus anti-BCMA CAR-T alone for relapsed or refractory multiple myeloma:a multicenter, open-label, randomized controlled trial |
| Year | 2019 |
| Country | china |
| Company sponsor | The Affiliated Hospital of Xuzhou Medical University |
| Cohort1: GC | |||||||||||||||
|
|||||||||||||||
| Cohort2: no GC | |||||||||||||||
|
|||||||||||||||